Corewell Health is the new name for Beaumont.

Learn More

AZD1222 COVID-19 Vaccine Clinical Trial

Beaumont AstraZeneca COVID-19 clinical trial
 

Announcing the New AZD1222 COVID-19 Vaccine Clinical Trial at Beaumont

Beaumont Health is excited to announce our involvement in the search for an effective vaccine for the COVID-19 coronavirus.


The vaccine that Beaumont will be testing is called AZD1222. It is expected that 40,000 people will be enrolled in this study across multiple countries, and Beaumont is looking to include hundreds of participants locally. This study will begin in November 2020 and participants will be followed for two years.


The study is called Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults.


Each eligible and enrolled participant will undergo two doses of the vaccine one month apart and will be followed periodically throughout the study. All interested individuals must be 18 years or older and meet an established set of inclusion criteria including the following:

 
  • you are 18 years of age or older
  • you are in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable)
  • you have an increased risk of getting COVID-19
  • you do not have a previously confirmed diagnosis of COVID-19

Thank You for Your Interest

Thank you for your interest in the AZD1222 COVID-19 Vaccine Clinical Trial. Due to the significant interest in participation within the community, Beaumont is temporarily pausing registration. Please monitor this site for updates as to when enrollment will be reopened.

About the Study

The study has 3 parts:

 
 

Screening Period

(up to 14 days)


You will visit the study center to see if the study is right for you, learn more about it, and decide whether you want to take part.

 
 

Study Treatment

(4 weeks)


You will visit the study center 2 or 3 times for study assessments. At 2 of these visits, you will receive the study injection (either the investigational vaccine or placebo). The study center staff will contact you by phone 7 days after each study injection.

 
 

Follow-Up Period

(about 2 years)


You will visit the study center up to 6 times for study assessments after you have received the study injections. Additional visits may be required if you develop signs of COVID-19 during the study.

Frequently Asked Questions

A clinical research study is a medical study that helps to answer important questions about an investigational vaccine or medicine, such as:

  • Does it work?
  • How safe is it?
  • Are there side effects?

All vaccines must be tested in clinical research studies before they can be approved to give to patients. Without people taking part in these studies, we would have no new vaccines.

There is currently no approved vaccine for COVID-19. In this study, participants will be randomly assigned (by chance) to receive 2 injections of either the investigational vaccine or placebo (4 weeks apart). A placebo looks like the investigational vaccine but contains no active vaccine. There is twice as much chance of receiving the investigational vaccine than of receiving the placebo.

If you take part, you will be in the AZD1222 COVID-19 VACCINE Study for about 2 years. You will need to:

  • Attend all study visits.
  • Be willing to receive regular contact (by phone, email, and/or text).
  • Notify the study team if you have any signs or symptoms of COVID-19.
  • The study team will explain the possible benefits and risks of the study.
  • You do not have to take part in the study if you don’t want to.
  • If you choose to take part in the study, you can stop participating at any time.
  • You will not be paid to take part in this study, but you may be reimbursed for reasonable travel costs during your participation.
  • The study injections and study-related tests will be provided at no cost to you.
  • A team of doctors and nurses will monitor your health carefully during the study.